GNLX

$2.63-$0.07 (-2.59%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$121.1M

45M shares

52-week range

$2.29 – $8.54

5% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-3.52

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$3M	+33022.5%	$-0.81	$-0.83–$-0.80	—	4
2027	$12M	+359.7%	$-0.76	$-0.76–$-0.76	—	3
2028	$88M	+620.0%	$-0.13	$-0.99–$0.64	—	4
2029	$188M	+114.5%	$0.71	$0.71–$0.71	3.7×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-13	$-0.20	$-0.21	-6.8%
2026-05-07	$-0.18	$-0.20	-11.1%
2026-03-19	$-0.22	$-0.24	-9.1%
2025-11-05	$-0.23	$-0.21	+8.7%
2025-08-07	$-0.22	$-0.20	+9.1%
2025-05-06	$-0.24	$-0.21	+12.5%
2025-03-28	$-0.17	$-0.26	-52.9%
2024-11-14	$-0.19

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
GNLXGenelux Corporation	$2.63	-2.59%	$118M	—
ACIUAC Immune S.A.	$2.57	-1.91%	$262M	—
ALDXAldeyra The	$1.44	-5.26%	$87M	—
CADLCandel Therapeutics, Inc.	$11.80	+10.49%	$865M	—
CLLSCellectis S.A.	$3.18	+7.25%

Genelux Corporation Common Stock

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

www.genelux.com

Employees: 26
IPO / List date: Jan 26, 2023
HQ: WESTLAKE VILLAGE, CA

Held by traders on TradeandTell

No one on the platform currently holds GNLX.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	12,200	$29.5K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded GNLX yet.

$GNLX chatter on StockTwits

Squeezy@TheRealShortSqueezyBullish19h
$ONCY : FDA Momentum Keeps Building 🧬 Oncolytics Biotech is entering an important stretch for pelareorep with strong clinical data and growing FDA support. 🔹 3 FDA Fast Track Designations across three cancer programs. 🔹 Colorectal cancer study showed a 33% response rate vs. ~10% historically, more than 3X higher. 🔹 Patients went 16.6 months without cancer worsening vs. 5.7 months, with median survival of 27 months vs. 11.2 months. 🔹 Colorectal cancer alone represents an estimated $3B–$5B annual opportunity. 🔹 Pelareorep has been evaluated in 1,300+ patients, with collaborations involving Roche, Pfizer, Incyte and others. 🔹 New U.S. patent protection extends through 2044. 📊 TECHNICAL SETUP: ONCY defended $0.77 support and is curling higher. Key levels: $0.85 → $0.93 → $1.08 → $1.18 → $1.30. Communicated Disclaimer: https://stockresearchtoday.com/oncy/ Sector Peers: $REPL $GNLX $CADL $CGON
View on StockTwits ↗
Richard Kupskey@KupperAug 5
$GNLX what's really sad is that this company is working on a cure for cancer and the people that try to bring it down and are manipulative have no morals or ethical values. That's just sad.
View on StockTwits ↗
KC1391@KC1391BullishAug 5
$GNLX why the big drop tho? No news… I feel this has a solid floor in the lows 2s and a ton of potential.
View on StockTwits ↗
Richard Kupskey@KupperAug 5
$GNLX this is absolutely rediculous. A bio company that has been around for years with a successful trial at each stage, and gets shit for support.
View on StockTwits ↗
M@justiceforb_85Jul 16
$GNLX primary completion date of 12/26 but company states data will be later this year? https://clinicaltrials.gov/study/NCT05281471?term=olvi-vec&rank=1
View on StockTwits ↗
Richard Kupskey@KupperJun 29
$GNLX This is getting rediculous. Up 10% and back down again.
View on StockTwits ↗
Richard Kupskey@KupperJun 22
$GNLX some day trading this again and playing games.
View on StockTwits ↗
William@Aawilliam2003Jun 17
$GNLX well a sell off like this has to be respected? Why? Because insider trading is running rampant these days and this looks like someone dumped hard
View on StockTwits ↗
Bryon K. Franzen@bkfViking123Jun 17
$GNLX flash crash
View on StockTwits ↗
ANP@AmaraNicJun 17
$GNLX what is happening
View on StockTwits ↗
SuperGreenToday@SuperGreenTodayJun 17
$GNLX Share Price: $3.04 Contract Selected: Jan 15, 2027 $2.5 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.73 – $0.89 Potential Upside: 62% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
William@Aawilliam2003Jun 9
$GNLX has their phase 3 completed enrollment? If not how can it report out in 2H26?
View on StockTwits ↗
ANP@AmaraNicJun 3
$GNLX half of the days volume hmmm…
View on StockTwits ↗
Richard Kupskey@KupperMay 29
$GNLX this should be at a minimum of $3.50 before it starts to run up when trial results are released.
View on StockTwits ↗
Richard Kupskey@KupperMay 29
$GNLX go ahead and play this short. Pay your premium and take your 10 percent. I have gone ling on this 3 times and made over 100% each time. Wake TF up.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.